Published: 25 March 2024
Author(s): Q. Perrier, V. Tuloup, C. Chevallier-Brilloit, P. Bedouch, S. Chanoine, Polyvalent immunoglobulin group
Issue: May 2024
Section: Letter to the Editor

Human normal polyvalent immunoglobulins (HNIg) have been widely used for the treatment of primary and secondary immune deficiencies. They also possess immunomodulatory properties and are employed in various other conditions. Despite an increase in the availability of immunoglobulin supply (with the introduction of subcutaneous immunoglobulins), the market has faced challenges due to several factors, including the scarcity of raw materials, complex production techniques [1], and the expansion of indications, particularly in neurology [2].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.